19 completed, 18 recruiting, 10 active not recruiting, 5 terminated. 59 Phase 2, 12 Phase 1, 3 Phase 3.
Follow relatlimab: new trials by email Literature Review of relatlimab trials Research Report on relatlimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer. Nivolumab, Gemcitabine, Cisplatin - Advanced Biliary Tract Cancer(BTC) | Phase 2 | Withdrawn | National Health Research Institutes, Taiwan | 2026-12-01 | 2026-07-02 | |
| Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis Nivolumab and Relatlimab, Melphalan - Metastatic Melanoma, Liver Metastases | Phase 1 / Phase 2 | Recruiting | University of Wisconsin, Madison | 15 | 2026-11-01 | 2026-10-30 |
| ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab Nivolumab, Relatlimab, Ipilimumab - Metastatic Melanoma, Advanced Melanoma | Phase 2 | Recruiting | NYU Langone Health | 90 | 2026-04-13 | 2026-08-24 |
| Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) Ipilimumab 3mg/kg and nivolumab 1mg/kg, Ipilimumab 1mg/kg Nivolumab 480mg and relatlimab 160mg, Nivolumab 480mg and relatlimab 160mg - Cutaneous Melanoma, Mucosal Melanoma | Phase 2 | Recruiting | Melanoma Institute Australia | 494 | 2026-02-09 | 2026-02-19 |
| Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab Nivolumab, Relatlimab, TMZ - Newly Diagnosed Glioblastoma | Phase 2 | Recruiting | Duke University | 92 | 2025-11-28 | 2026-09-17 |
| Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma Nivolumab, Relatlimab plus Nivolumab - Basal Cell Carcinoma | Phase 2 | Recruiting | University of California, San Diego | 30 | 2025-08-21 | 2026-07-28 |
| A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma LNS8801, Pembrolizumab, Chemotherapy (dacarbazine or temozolomide) - Melanoma (Skin Cancer), Melanoma Stage IIIB-IV | Phase 2 / Phase 3 | Recruiting | Linnaeus Therapeutics, Inc. | 135 | 2025-08-06 | 2026-04-22 |
| Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) Nivolumab, Relatlimab, Ipilimumab - Melanoma | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2024-12-31 | 2026-08-28 |
| Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma Biopsy Procedure, Biospecimen Collection, Lomustine - Progressive Glioblastoma, Recurrent Glioblastoma | Phase 2 | Suspended | National Cancer Institute (NCI) | 184 | 2024-11-08 | 2026-11-12 |
| Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer Biospecimen Collection, Bone Scan, Carboplatin - Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 156 | 2024-07-15 | 2026-11-06 |
| Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination - Cutaneous Squamous Cell Carcinoma | Phase 2 | Recruiting | Melanoma Institute Australia | 20 | 2024-06-21 | 2026-07-08 |
| Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma Nivolumab, Nivolumab + Relatlimab, Ipilimumab - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 90 | 2024-05-17 | 2026-04-01 |
| Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination - Merkel Cell Carcinoma | Phase 2 | Recruiting | Melanoma Institute Australia | 20 | 2024-03-11 | 2026-02-17 |
| Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab Nivolumab, Relatlimab - Urologic Neoplasms, Urogenital Neoplasms | Phase 2 | Active not recruiting | The Netherlands Cancer Institute | 90 | 2024-02-19 | 2026-07-15 |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography - Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 992 | 2024-02-02 | 2026-11-12 |
| A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma Relatlimab and nivolumab fixed dose combination (FDC) - Stage II Melanoma | Phase 2 | Active not recruiting | Melanoma Institute Australia | 20 | 2023-08-14 | 2026-02-05 |
| Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases BMS-986213 (Relatlimab-Nivolumab FDC), Nivolumab, Relatlimab - Melanoma (Skin) | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2023-02-23 | 2026-07-16 |
| Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab - Melanoma, Unresectable Melanoma | Phase 2 | Recruiting | NYU Langone Health | 105 | 2023-02-02 | 2026-10-28 |
| Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla Nivolumab, Relatlimab - Carcinomas, Renal Medullary Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2022-09-22 | 2026-10-07 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma Relatlimab, Nivolumab - Lymphoma, Non-Hodgkin, Hodgkin Disease | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 5 | 2022-09-13 | 2026-06-26 |
Showing 20 of 59. Sign in to see all of them.
Melanoma (15) · Neoplasms (4) · Recurrence (4) · Carcinoma, Hepatocellular (3) · Colonic Neoplasms (3) · Colorectal Neoplasms (3) · Lymphoma, Non-Hodgkin (3) · Multiple Myeloma (3) · Stomach Neoplasms (3) · Urinary Bladder Neoplasms (3) · Carcinoma, Basal Cell (2) · Carcinoma, Non-Small-Cell Lung (2) · Hematologic Neoplasms (2) · Hodgkin Disease (2) · Liver Neoplasms (2)
Bristol-Myers Squibb (15) · M.D. Anderson Cancer Center (5) · National Cancer Institute (NCI) (5) · Melanoma Institute Australia (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · Dan Zandberg (2) · NYU Langone Health (2) · The Netherlands Cancer Institute (2) · University Hospital, Essen (2) · Celgene (1) · Duke University (1) · Elizabeth Davis (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Inge Marie Svane (1) · Institut BergoniĆ© (1)
United States (43) · Australia (18) · Canada (12) · France (12) · Italy (12) · Spain (12) · Germany (11) · Netherlands (9) · United Kingdom (8) · Austria (7) · Belgium (6) · Mexico (6) · Switzerland (6) · Argentina (5) · Brazil (5)
Dung Le, MD (2) · Georgina Long (2) · Ahmad Tarhini, MD, PhD (1) · Arun Singh (1) · Brigette B Ma (1) · Dan P Zandberg, MD (1) · Dan Zandberg, MD (1) · Elizabeth Davis, MD (1) · Evan J Lipson, M.D. (1) · Georgina V Long (1) · Hearn J. Cho, M.D., Ph.D. (1) · Hussein Tawbi, MD, PHD (1) · Hussein Tawbi, MD,PHD (1) · Ines Da Silva (1)
PMID 26586415, PMID 28734759, PMID 29355075, PMID 30170630, PMID 31487218, PMID 32251400, PMID 32324435, PMID 32463741, PMID 33048619, PMID 33277223, PMID 34083421, PMID 34515338, PMID 34606846, PMID 34637336, PMID 34986285, PMID 35133871, PMID 35138919, PMID 35969233, PMID 36328377, PMID 36351402, PMID 36628573, PMID 36648215, PMID 36719749, PMID 36780608, PMID 37053535, PMID 37167764, PMID 37322121, PMID 37934000, PMID 38320023, PMID 38340723, PMID 38591867, PMID 38608691, PMID 38689060, PMID 38821718, PMID 38838311, PMID 38838316, PMID 39187595, PMID 39278994, PMID 39666929, PMID 39671533, PMID 39693587, PMID 39889250, PMID 39913886, PMID 40010775, PMID 40016450, PMID 40030000, PMID 40340830, PMID 40513285, PMID 40638872, PMID 40865033
2018 (4), 2016 (2), 2023 (2), U10CA180820 (2), U10CA180821 (2), 2015 (1), 2019 (1), P50CA062924 (1), U10CA180868 (1), U24CA196172 (1)